A new class of drugs for a novel biologic target
Breakthrough science in the most advanced
therapeutic program for this receptor
Our lead asset FT011 will be Phase 3-ready for SSc in 2023; the follow-on drug OCX063 also enters Phase 2 in 2023 for CKD and FSG.
Certa Therapeutics is focused on the emerging field of medical science which uses genetic information to identify which patients will best respond to a specific treatment, commonly referred to as precision medicine.
Precision medicine uses diagnostic tests to treat the right patients at the right time based on their genetic make-up and stage of disease. It is an individual tailored approach to medicine. Here, it involves looking at the patient’s genetic and molecular characteristics of their disease and uses this information to identify the inflammatory pathways that led to fibrosis. This informs the treatment approach that will be best suited to the patient, by providing a targeted therapy that can provide the best outcome for that patient.
The research conducted on the new candidate therapies being developed by Certa Therapeutics includes efficacy studies, where multiple models of fibrotic diseases have shown positive impact on organ function following treatment with these new drugs.
Scleroderma: a rare and potentially life-threatening autoimmune disorder characterised by inflammation and fibrosis of the skin and other organs.
Chronic Kidney Disease
Chronic kidney disease (CKD) encompasses all degrees of decreased kidney function, from mild or moderate disease to severe and end organ failure.
Focal Segmental Glomerulosclerosis
Focal segmental glomerulosclerosis is one of the many kidney conditions described under the umbrella of glomerulonephritis (inflammation of the kidney), which can lead to chronic kidney disease. FSGS is a condition that results in hardening or thickening of the glomeruli, which act as filters inside the nephrons of the kidney.
Diabetic nephropathy, or diabetic kidney disease (DKD) is a common complication of diabetes, where there is a decline in kidney function and reduced ability to filter out excess proteins from the blood.
Fibrosis is observed in multiple eye diseases, including diabetic retinopathy (DR) and age-related macular degeneration (AMD), where the deposition of scar tissue is irreversible, impacting vision and, in the case of DR, can ultimately lead to blindness.
All of the candidate drugs described on this site are investigational products which have not received marketing authorization or approval by any regulatory agency, including the US Food and Drug Administration, the European Medicines Agency, or the Australian Therapeutic Goods Agency. The investigational drug products are undergoing clinical studies to evaluate the safety and effectiveness in humans.